Prairie Capital buys Seraplex, adding to its biospecimen roster
What's the deal? Prairie CapitalDealroom has a profile for this one. Try Dealroom →, a Chicago-based private equity firm, has acquired SeraplexDealroom has a profile for this one. Try Dealroom →, a California specialty blood products company. WaveEdge CapitalDealroom has a profile for this one. Try Dealroom → served as exclusive sell-side M&A advisor. The deal was announced October 1, 2026; terms were not disclosed.
What each side brings: Seraplex has supplied global diagnostic and therapeutic manufacturers for over five decades, expanding beyond standard specimens into specialty and disease-state products. Prairie Capital is a multi-sector investor that backs founder-owned companies and builds them into larger platforms.
What's the endgame? Prairie is folding Seraplex into a consortium of biospecimen companies. "The integration of Seraplex with a consortium of Prairie biospecimen companies has resulted in a formidable suite of products and services supporting the biopharmaceutical and diagnostic industries," said Rose Maljanian, managing director at WaveEdge.
Why now? Demand for specialty blood products is rising as precision medicine, biomarker discovery, and new therapeutic development accelerate.
The signal: The deal reflects steady consolidation in the life sciences supply chain, as private equity assembles biospecimen platforms to serve a growing drug-development and diagnostics market.
Read more: prnewswire.com
Image credit: WHEATON Products
